Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EFZT | ISIN: SE0020181014 | Ticker-Symbol: MVR0
Frankfurt
04.11.24
09:17 Uhr
0,215 Euro
+0,016
+8,04 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDIVIR AB Chart 1 Jahr
5-Tage-Chart
MEDIVIR AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,2280,28719:09

Aktuelle News zur MEDIVIR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:09Medivir signs new clinical trial collaboration with Eisai3
25.10.Medivir's CEO to "Fostrox is unique in its kind"1
18.09.Medivir to present at the Pareto Securities Healthcare Conference2
17.09.Medivir - live from ESMO in Barcelona1
16.09.Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO1
12.09.Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 161
22.08.Medivir AB GAAP EPS of -SEK 0.32, net turnover of SEK 1.1M1
22.08.Medivir AB: Interim Report January - June 2024136"Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer" STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- April - June Financial summary for the quarter Net...
► Artikel lesen
18.07.Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September1
28.06.Number of shares and votes in Medivir AB on 28 June 20242
27.06.Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI1
19.06.Medivir Selects CRO Partner for Planned Phase 2b Study2
19.06.Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility140STOCKHOLM, June 19, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
► Artikel lesen
30.05.MEDIVIR: Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 20243
30.05.Medivir to present at Redeye Growth Day2
23.05.Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program190STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
30.04.Medivir AB: Interim Report January - March 2024153"Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima...
► Artikel lesen
25.04.Medivir AB: FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease269STOCKHOLM, April 25, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
23.04.Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue237STOCKHOLM, April 23, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
15.04.Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701122STOCKHOLM, April 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
► Artikel lesen
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1